CAJ | 학술논문

目的评价铜绿假单胞菌注射液联合新辅助化疗治疗局部晚期乳腺癌的安全性和有效性.方法局部晚期乳腺癌患者42例,随机分为两组,其中试验组患者20例,对照组22例.两组均采用TEC化疗方案,试验组加用铜绿假单胞菌注射液.治疗结束后评估疗效,并比较两组治疗的安全性以及患者的耐受性.结果临床疗效结果显示试验组RR率为75.0%(15例),高于对照组的54.6%(12例)(P<0.01);试验组有9例出现不良反应,4例给予特殊处理,其余均自行缓解.结论铜绿假单胞菌注射液能明显提高化疗对局部晚期乳腺癌的疗效且安全性良好,是治疗乳腺癌的一种良好的辅助用药.
목적 평개동록가단포균주사액연합신보조화료치료국부만기유선암적안전성화유효성.방법 국부만기유선암환자42례,수궤분위량조,기중시험조환자20례,대조조22례.량조균채용TEC화료방안,시험조가용동록가단포균주사액.치료결속후평고료효,병비교량조치료적안전성이급환자적내수성.결과 림상료효결과현시시험조RR솔위75.0%(15례),고우대조조적54.6%(12례)(P<0.01);시험조유9례출현불량반응,4례급여특수처리,기여균자행완해.결론 동록가단포균주사액능명현제고화료대국부만기유선암적료효차안전성량호,시치료유선암적일충량호적보조용약.
Objective To evaluate the safety and efficacy of neoadjuvant chemotherapy combined with PA-MSHA injection for the treatment of locally advanced breast cancer. Methods An open, randomized, controlled clinical trial was conducted in this study. 42 locally advanced breast cancer patients were randomly assigned to two groups, namely the experimental group (20 cases) and control group (22 cases). All the patients received chemotherapy of TEC regimen, while, in addition, the patients in experiment group received PA-MSHA injection. After the treatment, the efficacy of treatment was evaluated. The safety and tolerance of patients were also measured during the treatment. Results The overall response rate (CR+PR) [75.0 %(15/20)]in the experiment group was significant higher than that [54.6 %(12/22)]in control group (P < 0.01). Adverse reactions were found for 9 cases in experiment group, four of whom received medical care while the others recovered automatically. Conclusion PA-MSHA injection can significantly enhance the efficaey of neoadjuvant chemotherapy on the patients with locally advanced breast cancer. The PA-MSHA injection which has been proved safety in treatment is an ideal supplementary therapy for breast cancer.